Skip to content
TrialMatch
Sign up
Recruiting

Mediastinal Lymph Node Dissection Versus Spared Mediastinal Lymph Node Dissection in Stage I GGN NSCLC

Create a profile to match View the full record on ClinicalTrials.gov

About this study

Lung cancer is the leading cause of cancer related death worldwide. Lobectomy or sub-lobectomy with mediastinal lymph node dissection is the standard surgery. About 50% lung nodules are pure ground-glass or part-solid nodules. Non-solid nodules rarely develop mediastinal lymph node metastasis. The present study is a prospective, multicenter and randomized clinical trial, comparing the overall survival and disease-free survival of whether performing mediastinal lymph node dissection in non-small cell lung cancer with ground-glass nodule CT features.

Condition
Lung Neoplasms, Lymph Node Excision
Tested
Systemic mediastinal lymph node dissection, Spared mediastinal lymph node dissection
Sponsor
Tianjin Medical University Cancer Institute and Hospital

Who can join

Age
Not specified
Sex
All sexes
Healthy volunteers
Not accepted

Inclusion 5

  • Study condition: Lung Neoplasms, Lymph Node Excision
  • Thin-slice HRCT shows single GGN with C/T ≤ 0.5 and no lymph node metastasis;
  • Clinical stage IA NSCLC (TNM 8th classification) diagnosed prior or in surgery;
  • No history of malignancies within past 5 years or lung surgery;
  • No anti-cancer treatment prior to surgery.

Exclusion 5

  • Simultaneous or metachronous (within the past 5 years) double cancers;
  • Active bacterial or fungous infection;
  • Interstitial pneumonitis, pulmonary fibrosis, or severe pulmonary emphysema;
  • Systemic steroidal medication;
  • Uncontrollable diabetes mellitus; (vi) Uncontrollable hypertension or history of severe heart disease, heart failure.

Where

1 site, 1 recruiting

Ethics review board of Tianjin Medical University Cancer Institute and Hospital

Tianjin, Tianjin Municipality, China

Recruiting

Contact

Potential match only. Final eligibility is determined by the study team.